Xilio Therapeutics (XLO) Other Non Operating Income (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Other Non Operating Income data on file, last reported at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income rose 118.94% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (down 31.97% YoY), and the FY2025 full-year result was $1.1 million, down 52.97% from the prior year.
• Other Non Operating Income advanced to $1.3 million in Q1 2026, from $921000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $1.3 million in Q1 2026 to a low of -$1.4 million in Q2 2025.
• A 5-year average of $493000.0 and a median of $613000.0 in 2023 frame the typical range for Other Non Operating Income.
• Across the five-year window, Other Non Operating Income jumped 1347.54% in 2023 and slumped 283.31% in 2025, its largest moves.
• Tracing XLO's Other Non Operating Income over 5 years: stood at $701000.0 in 2022, then tumbled by 32.24% to $475000.0 in 2023, then advanced by 12.84% to $536000.0 in 2024, then soared by 71.83% to $921000.0 in 2025, then soared by 39.31% to $1.3 million in 2026.
• Business Quant data shows XLO's Other Non Operating Income at $1.3 million in Q1 2026, $921000.0 in Q4 2025, and $1.0 million in Q3 2025.